Among 45 O/MM patients (67.2%), median PFS was 12 months (3–59+), median OS 23 months (4–119+): in KRAS2–4/NRAS2–4/BRAF15 wt and mut, median PFS was 18 (5–24 months) and 12 months (3–59+ months), median OS was 28 (10+-70+ months) and 21 months (4–119+ months), respectively, not significantly different (P 0.624 and 0.538 respectively). The gene discussed is KRAS; the disease is Miyoshi myopathy.